Evidence map›Paper›PMID 32444261›Full record

ArticleEuropean urology2020

The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series.

Armando Stabile, Clement Orczyk, Francesco Giganti, Marco Moschini, Clare Allen, Shonit Punwani, Nathalie Cathala, Hashim U Ahmed, Xavier Cathelineau, Francesco Montorsi and 4 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Surveillance after Focal Therapy - a Comprehensive Review.Prostate cancer and prostatic diseases · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Focal therapy for localized prostate cancer - Current status.Indian journal of urology : IJU : journal of the Urological Society of India
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Armando StabileDepartment of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France. Electronic address: armando.stabile88@gmail.com.
Clement OrczykDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, University College London, London, UK.
Francesco GigantiDivision of Surgery and Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
Marco MoschiniDepartment of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France; Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.
Clare AllenDepartment of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
Shonit PunwaniDepartment of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
Nathalie CathalaDepartment of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
Hashim U AhmedDivision of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Xavier CathelineauDepartment of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
Francesco MontorsiDepartment of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Mark EmbertonDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, University College London, London, UK.
Alberto BrigantiDepartment of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Rafael Sanchez-SalasDepartment of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
Caroline M MooreDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, University College London, London, UK.
University College London Hospitals NHS Foundation Trust · GBUniversité Paris Cité · FRVita-Salute San Raffaele University · ITImperial College Healthcare NHS Trust · GB

Funding

Wellcome Trust 204998/Z/16/Z
6 · The paper itself

Abstract

Focal therapy (FT) for prostate cancer (PCa) is emerging as a novel therapeutic approach for patients with low- to intermediate-risk disease, in order to provide acceptable oncological control, whilst avoiding the side effects of radical treatment. Evidence regarding the ideal follow-up strategy and the significance of prostate-specific antigen (PSA) kinetics after treatment is needed. In this study, we aimed to assess the value of the percentage of PSA reduction (%PSA reduction) after FT in predicting the likelihood of any additional treatment or any radical treatment. We retrospectively analysed a multicentre cohort of 703 men receiving FT for low- and intermediate-risk PCa. Overall, the rates of any additional treatment and any radical treatment were 30% and 13%, respectively. The median follow-up period was 41 mo. The median %PSA reduction after FT was 73%. At Cox multivariable analysis, %PSA reduction was an independent predictor of any additional treatment (hazard ratio [HR]: 0.96; p < 0.001) and radical treatment (HR: 0.97; p < 0.001) after FT. For %PSA reduction of>90%, the probability of any additional treatment within 5 yr was 20%. Conversely, for %PSA reduction of <10%, the probability of receiving any additional treatment within 5 yr was roughly 70%. This study is the first to assess the role of %PSA reduction in the largest multicentre cohort of men receiving FT for PCa. Given the lack of standardised follow-up strategies in the FT field, the use of the %PSA reduction should be considered. PATIENT SUMMARY: The percentage of prostate-specific antigen reduction is a useful tool to assess men following focal therapy (FT). It can assist the urologist in setting up an appropriate follow-up and during post-FT patient counselling.

Indexed as

High-Intensity Focused Ultrasound AblationAgedHumansMaleMiddle AgedProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesTreatment OutcomeProstate-Specific AntigenFocal therapyHigh-intensity focused ultrasoundMinimally invasive therapyOutcomeProstate cancerTherapy

Identifiers

PMID32444261
OpenAlexW3026839641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.